top of page

HyperQure™

Designed To Do What Others Cannot

HyperQure is a next-generation renal denervation system that delivers what catheter-based solutions are unable to – safety, precision, and complete denervation.

Header - crop as you wish Marcus.png
Generator_edited.JPG

Generator

  • "Base unit" that generates RF frequency for nerve ablation

  • Serves as the control unit to set RF energy intensity

Shaft and Electrode.jpg

Shaft and electrode

  • The portion of the instrument that enters the patient to perform renal denervation

  • Electrode guide assembly wraps around the renal artery to deliver RF energy

Handle (top).jpg

Handle (top)

  • Forward switch toggles between two diameters of the electrode guide according to artery size

  • Rear switch extends and retracts the electrode guide

Handle (bottom).jpg

Handle (bottom)

  • Activation switch that triggers the delivery of RF energy for denervation, with a protective cover to prevent accidental activation

  • In the unlikely event of a malfunction, the emergency release system safely releases the electrode guide when actuated

Engineered for Precision and Simplicity

HyperQure is built for laparoscopic use, with an intuitive workflow that enables surgeons to achieve complete denervation.

Why Existing RDN Systems Fall Short

Renal denervation is proven in principle, but current solutions haven’t worked well.
Why? Because they rely on catheters that miss key nerves and carry procedural risks.

catheter.JPG

Risk of Vascular Damage

Energy delivered from inside the artery can harm the endothelium, raising safety concerns

random distribution.png

Incomplete Nerve Ablation

Renal nerves are randomly scattered along the artery’s outer wall — nearly one-third of them lie beyond the reach of catheter-based systems

accessory artery.jpg

Poor Anatomical Fit

Due to anatomical variation, nearly 50% of patients may be ineligible for current RDN treatments due to branch or accesory arteries

HyperQure Solves What Catheters Can't

As the only extravascular RDN system in development, HyperQure is designed to deliver complete denervation for most patients

– regardless of vascular or nerve anatomy.

Our published research explores this advantage in depth.

Standalone 1.jpg
20250117_0926___Left 수술사진 - SP 로봇.jpg

On the Path to FDA Approval

HyperQure is now undergoing first-in-human trials in Korea and on its way towards FDA approval, for a new standard of RDN techology on the global stage.


If you are interested in learning or exploring collaboration, let's connect.

bottom of page